BR9813254A - Antìgeno enterococcus e vacinas - Google Patents

Antìgeno enterococcus e vacinas

Info

Publication number
BR9813254A
BR9813254A BR9813254-7A BR9813254A BR9813254A BR 9813254 A BR9813254 A BR 9813254A BR 9813254 A BR9813254 A BR 9813254A BR 9813254 A BR9813254 A BR 9813254A
Authority
BR
Brazil
Prior art keywords
antigen
carrier
vaccines
galactose
enterococcus antigen
Prior art date
Application number
BR9813254-7A
Other languages
English (en)
Inventor
Ali Ibrahim Fattom
Ramesh K Sood
Sara E Shepherd
Original Assignee
Nabi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabi filed Critical Nabi
Publication of BR9813254A publication Critical patent/BR9813254A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Patente de Invenção: "ANTìGENO ENTEROCOCCUS EVACINAS". Uma maioria de isolados clínicos de E. faecalis e de E.faecium se encaixa em dois grupos e três grupos, respectivamente.Os antígenos distintos são associados com cada um dos cincogrupos. Os antígenos de Enterococcus são facilmente obtidos decepas de E. faecalis e de E. faecium e podem induzir a produçãode anticorpos protetores. Conseq³entemente, os antígenos sãoúteis para vacinas que protegem contra infecção por isolados deEnterococcus clinicamente significantes (patogênicos). Osantígenos e anticorpos gerados para os antígenos são tambémúteis nos testes diagnósticos.
BR9813254-7A 1997-10-14 1998-10-14 Antìgeno enterococcus e vacinas BR9813254A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/949,757 US6756361B1 (en) 1997-10-14 1997-10-14 Enterococcus antigens and vaccines
PCT/US1998/021561 WO1999018996A1 (en) 1997-10-14 1998-10-14 Enterococcus antigens and vaccines

Publications (1)

Publication Number Publication Date
BR9813254A true BR9813254A (pt) 2001-11-20

Family

ID=25489514

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9813254-7A BR9813254A (pt) 1997-10-14 1998-10-14 Antìgeno enterococcus e vacinas

Country Status (14)

Country Link
US (2) US6756361B1 (pt)
EP (3) EP1028749B1 (pt)
JP (2) JP2001519402A (pt)
AT (1) ATE397456T1 (pt)
AU (1) AU754890B2 (pt)
BR (1) BR9813254A (pt)
CA (1) CA2306476A1 (pt)
CY (1) CY1108307T1 (pt)
DE (1) DE69839587D1 (pt)
DK (1) DK1028749T3 (pt)
ES (1) ES2308818T3 (pt)
NZ (1) NZ504501A (pt)
PT (1) PT1028749E (pt)
WO (1) WO1999018996A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905670B2 (en) 1995-03-28 2005-06-14 The General Hospital Corporation Methods of screening compounds useful for prevention of infection or pathogenicity
KR100217772B1 (ko) * 1996-09-03 1999-09-01 최진호 조명기기의 램프 과열방지 장치 및 방법
US6756361B1 (en) * 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
US7078584B2 (en) 2000-03-17 2006-07-18 The General Hospital Corporation Salmonella typhimurium-infected Caenorhabditis elegans for identifying inhibitors of infection
US7112716B2 (en) 2000-04-06 2006-09-26 The General Hospital Corporation Methods for screening and identifying host pathogen defense genes
US6710403B2 (en) 2002-07-30 2004-03-23 Fairchild Semiconductor Corporation Dual trench power MOSFET
EP2327720A1 (en) * 2003-05-30 2011-06-01 Intercell AG Enterococcus antigens
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US20060165716A1 (en) 2004-07-29 2006-07-27 Telford John L Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
KR20070104590A (ko) * 2005-01-10 2007-10-26 나비 바이오파마슈티컬즈 스타필로코쿠스 아우레우스 감염을 치료하는 방법
US20110223197A1 (en) 2005-10-18 2011-09-15 Novartis Vaccines And Diagnostics Inc. Mucosal and Systemic Immunization with Alphavirus Replicon Particles
JP5215865B2 (ja) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
AU2007281934B2 (en) 2006-01-18 2012-11-15 University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
WO2007109810A2 (en) * 2006-03-23 2007-09-27 Novartis Ag Methods for the preparation of imidazole-containing compounds
CA2646891A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
WO2007141278A2 (en) 2006-06-06 2007-12-13 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
EP2027155B1 (en) 2006-06-06 2016-01-27 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
JP5658564B2 (ja) 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
AU2008299376B2 (en) 2007-09-12 2013-02-28 Glaxosmithkline Biologicals S.A. GAS57 mutant antigens and GAS57 antibodies
KR101773114B1 (ko) 2007-12-21 2017-08-30 노파르티스 아게 스트렙토라이신 ｏ의 돌연변이 형태
BRPI0920041A2 (pt) 2008-10-06 2017-06-27 Univ Chicago composições e processos relacionados às proteínas eap, emp e/ou adsa bacterianas
AU2010204139A1 (en) 2009-01-12 2011-08-11 Novartis Ag Cna_B domain antigens in vaccines against gram positive bacteria
BRPI1010307B1 (pt) 2009-04-03 2021-07-27 University Of Chicago Polipeptídeos variantes de proteína a (spa), composição imunogênica compreendendo os mesmos, vacina, método de produção da referida vacina, bem como uso dos referidos polipeptídeos
ES2596653T3 (es) 2009-06-16 2017-01-11 Glaxosmithkline Biologicals Sa Ensayos bactericidas de opsonización y dependientes de anticuerpo mediado por el complemento de alto rendimiento
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
RU2559543C2 (ru) * 2010-01-19 2015-08-10 Универзитетсклиникум Фрайбург Компоненты энтерококковых клеточных стенок и их антибактериальные применения
JP2013523818A (ja) 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
ES2655701T3 (es) 2010-07-02 2018-02-21 The University Of Chicago Composiciones y métodos relacionados con variantes de la proteína A (SpA)
US9095540B2 (en) 2010-09-09 2015-08-04 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
CA2817973C (en) 2010-10-15 2019-06-25 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
DK2526951T3 (en) * 2011-05-27 2016-01-04 Universitätsklinikum Freiburg Rhamnopolysaccharid from Enterococcus faecium clone 17 complex and uses thereof
CN103906535B (zh) 2011-08-15 2017-07-14 芝加哥大学 与葡萄球菌蛋白a的抗体相关的组合物和方法
CN104768572B (zh) 2012-04-26 2021-08-24 芝加哥大学 葡萄球菌凝固酶抗原及其使用方法
EP2841101B1 (en) 2012-04-26 2019-08-07 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
WO2014013375A1 (en) 2012-07-16 2014-01-23 Pfizer Inc. Saccharides and uses thereof
US10125373B2 (en) 2013-01-22 2018-11-13 Arizona Board Of Regents On Behalf Of Arizona State University Geminiviral vector for expression of rituximab
EP3415160B1 (en) * 2014-03-04 2021-08-18 Klinikum der Universität München Polypeptides derived from enterococcus and their use for vaccination and the generation of therapeutic antibodies
WO2017173398A1 (en) 2016-04-01 2017-10-05 Duke University Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform
WO2019183500A1 (en) 2018-03-23 2019-09-26 Hung Chiung Yu Coccidioides antigens and methods of their use

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2466251B1 (fr) * 1979-10-03 1983-03-18 Agronomique Inst Nat Rech Vaccin animal anticolibacillaire, obtention et application
US4439422A (en) 1980-01-02 1984-03-27 Research Corporation Group B Streptococcus antigens and vaccines
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
JPS5927833A (ja) * 1982-08-06 1984-02-14 Advance Res & Dev Co Ltd コレステロール乃至トリグリセリド低下剤
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
FR2546756B1 (fr) * 1983-06-03 1985-11-29 Centre Nat Rech Scient Nouveaux derives immunostimulants, leur preparation et leur application comme medicament
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
JPS6028401A (ja) 1983-07-27 1985-02-13 Advance Res & Dev Co Ltd トリグリセリド低下活性多糖類
US4626502A (en) * 1984-01-27 1986-12-02 Abbott Laboratories Method for exposing bacterial antigen in bacterial cells assay using same
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
GB8414273D0 (en) * 1984-06-05 1984-07-11 Oxoid Ltd Identifying streptococcal grouping
JPS615022A (ja) * 1984-06-19 1986-01-10 Advance Res & Dev Co Ltd 腸内細菌叢改善剤
GB8517895D0 (en) * 1985-07-16 1985-08-21 Technology Licence Co Ltd Monoclonal antibodies
US4695524A (en) * 1986-05-21 1987-09-22 Xerox Corporation Process for ultra high quality images with magnetic developer composition
US5143845A (en) * 1986-09-03 1992-09-01 Toa Pharmaceutical Co., Ltd. Mixture of saccarifying lactic acid producing and butyric acid producing bacteria
EP0285649A4 (en) * 1986-10-08 1990-06-27 David Bernstein METHOD FOR EXPOSING ANTIGENS OF GROUP A STREPTOCOCCUS AND IMPROVED DIAGNOSTIC TEST FOR THE IDENTIFICATION OF GROUP A STREPTOCOCCUS
US5032505A (en) 1988-11-21 1991-07-16 Chembiomed, Ltd. Inhibitors for glycosaminosyl transferase V
US5175279A (en) * 1989-01-19 1992-12-29 Hakuto Co., Ltd. Polysaccharide, and water absorbent, moisture absorbent or humectant and thickening agent chiefly made of the polysaccharide
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5010062A (en) * 1989-09-25 1991-04-23 Vanderbilt University Therapeutic agent and method of inhibiting vascularization of tumors
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5858728A (en) * 1991-03-13 1999-01-12 Common Services Agency Monoclonal antibody against LPS core
US5225331A (en) * 1991-04-25 1993-07-06 National Research Council Of Canada Immunoassay for detecting group b streptococcus
US5205917A (en) * 1991-05-07 1993-04-27 Glyko, Inc. Fluorophore assisted carbohydrate electrophoresis diagnosis
ATE232730T1 (de) * 1991-08-23 2003-03-15 Alberta Res Council Verfahren und zusammensetzungen zur verhinderung der antikörper-vermittelten abstossung von xenogenen transplantaten
US5478557A (en) * 1992-07-29 1995-12-26 The United States Of America, As Represented By The Secretary Of Agriculture Probiotic for control of salmonella
RU2101029C1 (ru) * 1992-11-26 1998-01-10 Товарищество с ограниченной ответственностью "ХИМЭК" Способ получения препарата для идентификации стрептококка группы д
GB9310468D0 (en) * 1993-05-20 1993-07-07 Oxford Glycosystems Ltd Sugar complexes
US5367058A (en) * 1993-08-25 1994-11-22 Becton, Dickinson And Company Modified antibodies with increased affinity
JPH0782158A (ja) * 1993-09-16 1995-03-28 Yakult Honsha Co Ltd 抗腫瘍剤
JP2717497B2 (ja) * 1993-12-28 1998-02-18 不二ラテックス株式会社 酸性多糖類被覆コンドーム
GB9401689D0 (en) * 1994-01-28 1994-03-23 Univ Manchester Diagnosis and treatment of endocarditis
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US5489302A (en) * 1994-05-24 1996-02-06 Skottun; Bernt C. Accommodating intraocular lens
JPH0827010A (ja) * 1994-07-19 1996-01-30 Nichinichi Seiyaku Kk 制癌免疫療法剤
US5700787A (en) * 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5871751A (en) * 1994-10-12 1999-02-16 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Renibacterium salmoninarum vaccine and method for its preparation
US5569366A (en) * 1995-01-27 1996-10-29 Beckman Instruments, Inc. Fluorescent labelled carbohydrates and their analysis
US5760213A (en) * 1995-06-05 1998-06-02 Tayca Corporation Immunoactivating agent
US5695768A (en) * 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
DE19524515A1 (de) * 1995-07-05 1997-01-09 Deutsches Krebsforsch Saccharid-Konjugate
US6722062B2 (en) * 1997-08-20 2004-04-20 The Brigham And Women's Hospital, Inc. Capsular polysaccharides from enterococci
WO1999008705A1 (en) * 1997-08-20 1999-02-25 Brigham And Women's Hospital Capsular polysaccharides from enterococci
US6756361B1 (en) * 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
US7030101B2 (en) * 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of β-glucans and specific antibodies
WO2000015238A1 (en) * 1998-09-14 2000-03-23 Nabi COMPOSITIONS OF β-GLUCANS AND SPECIFIC IGIV
TR200103231T2 (tr) * 1999-03-12 2002-03-21 University Of Massachusetts Lipoglikan bileçimleri ve parazit enfeksiyonlarìnì tedavi etme metotlarì
US6720160B2 (en) * 2001-10-11 2004-04-13 Helica Biosystems, Inc. Method for simultaneous detection of multiple microbial antigens in biological specimens from mastitic animals

Also Published As

Publication number Publication date
DK1028749T3 (da) 2008-09-01
DE69839587D1 (de) 2008-07-17
US7291343B2 (en) 2007-11-06
ATE397456T1 (de) 2008-06-15
JP2001519402A (ja) 2001-10-23
PT1028749E (pt) 2008-09-04
EP1028749B1 (en) 2008-06-04
JP2009227680A (ja) 2009-10-08
WO1999018996B1 (en) 1999-06-03
US20050008658A1 (en) 2005-01-13
EP1028749A4 (en) 2003-03-12
US6756361B1 (en) 2004-06-29
WO1999018996A1 (en) 1999-04-22
AU754890B2 (en) 2002-11-28
CY1108307T1 (el) 2014-02-12
ES2308818T3 (es) 2008-12-01
NZ504501A (en) 2003-09-26
EP1970073A1 (en) 2008-09-17
EP1028749A1 (en) 2000-08-23
EP2269635A1 (en) 2011-01-05
AU9694998A (en) 1999-05-03
CA2306476A1 (en) 1999-04-22

Similar Documents

Publication Publication Date Title
BR9813254A (pt) Antìgeno enterococcus e vacinas
WO1998058668A3 (en) Bordetella pertussis antigens as carriers in vaccinating conjugates and oral vaccines comprising bordetella pertussis fimbriae
IL102687A (en) Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
AU8316701A (en) Anti-dual integrin antibodies, compositions, methods and uses
DE122010000015I1 (de) Kombinierte Impfstoffe, die Hepatitis-B-Oberflächen antigen und andere Antigene enthalten
EP0866133A3 (en) A group b streptococcus vaccine
FI903292A0 (fi) T-cellepitop som baerarmolekyler foer konjugerade vacciner.
ATE237687T1 (de) Rekombinierte sequenzen des monoklonalen anti- idiotypischen antikörpers 3h1, diean dem menschlichen karzioembyonischen antigen liiert sind
AU628948B2 (en) Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof
DK0473721T3 (da) Antiidiotypisk antistof, som fremkalder en immunreaktion med et glycosphingolipid, og anvendelse deraf
WO2001079259A8 (en) Javelinization of protein antigens to heat shock proteins
EP2057999A3 (en) Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
IL109445A0 (en) Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
ATE530572T1 (de) Antigen-cocktails, p35 und verwendungen dafür
EP0153871A3 (en) Antibody enhancement of immunogenicity of antigen
AU4803785A (en) Cross-reactive and protective epitopes of circumsporozoite proteins
DK101196A (da) Histaminderivat, histamin-immunogen-konjugat samt antistof fremstillet mod konjugatet
CA2333598A1 (en) Toxoplasma gondii antigens, p35, and uses thereof
EP0485476A4 (en) Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
AU622548B2 (en) Novel tumor-associated antigen, antibodies, compositions and uses therefor
GB2267148B (en) Footrot antigens,vaccines and diagnostic assays
AU1626492A (en) Monoclonal antibodies against the plasmin-antiplasmin complex, a method for the preparation thereof and the use thereof
FR2775189B1 (fr) Compositions anti-tumorales a base d'antigenes hla-g ou d'anticorps anti-hla-g
MX9704225A (es) Fragmentos de anticuerpos monoclonales que tienen actividad inmunosupresora.
MX9707295A (es) Metodo para mejorar la respuesta de los anticuerpos a los antigenos especificos con interleucina-10.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25K Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication

Owner name: NABI BIOPHARMACEUTICALS (US)

Free format text: REFERENTE A RPI 1793 DE 17/05/2005, COD. DE DESPACHO 25.4, QUANTO AO NOME DO TITULAR.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO O PRESENTE PEDIDO.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS ANUIDADES EM DEBITO.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2316 DE 26-05-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.